Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TLN-499 and Venetoclax in Relapsed/Refractory Solid Tumors
NCT07713732Phase 1Recruiting
- Sponsor
- Treeline Biosciences
- Start
- Aug 2026
- Primary completion
- Aug 2030
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TLN-499 in small cell lung cancer (SCLC), neuroendocrine cancer, malignant pleural mesothelioma (MPM) and 1 more, sponsored by Treeline Biosciences. Primary endpoints: Incidence of Dose-Limiting Toxicities at 35 days, Incidence of Adverse Events and Serious Adverse Events at 2 years and 1 more. Started Aug 2026; status: recruiting.
02
Drugs
TLN-499
03
Conditions
small cell lung cancer (SCLC)neuroendocrine cancermalignant pleural mesothelioma (MPM)synovial sarcoma (SS)
Beyond the preview
Go deeper on NCT07713732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07713732.